NCT05618041View on ClinicalTrials.gov

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

September 6, 2027

Study Completion Date

December 6, 2027

Conditions

Acute Lymphoblastic LeukemiaLymphomaMultiple Myeloma

Interventions

BIOLOGICAL

CAR-T Autologous T cell injection

Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis

Trial Locations (1)

Unknown

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors

collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | Biotech Hunter | Biotech Hunter